Abstract: An improved cholesterol-lowering tablet is manufactured by blending tablet grade cholestyramine with an appropriate amount of lubricant and directly compressing into elongated tablets having a specified thickness. These inner tablets are successfully film coated using aqueous film-coating processes without tablet preheating and by simultaneous spray-drying.

Abstract: Improved oral dosage formulations for acid-labile dideoxy purine nucleoside derivatives such as ddA, ddI, and ddG, have been developed by incorporating selected water-insoluble buffering systems in the formulation. These novel formulations provide reduced mass dosage units in the form of convenient, palatable chewable/dispersible tablets or a dry powder sachet. The reduced mass requirement, necessary to allow tablets of reasonable size, was achieved in part by an unexpected 20 to 25% increase in drug bioavailability resulting from use of the selected buffering systems comprised of an insoluble magnesium antacid agent and either dihydroxyaluminum sodium carbonate or calcium carbonate.